TELA Bio (TELA) outlines severance, equity and benefits for departing CEO

Rhea-AI Filing Summary

TELA Bio, Inc. amended a prior report to detail the separation agreement with former Chief Executive Officer Antony Koblish, whose role ended on August 3, 2026. As of the August 7, 2026 effective date, Mr. Koblish receives accrued salary through his separation date and eligibility to elect continued health, dental and vision coverage through August 31, 2026.

He is entitled to 12 months of base salary, paid in regular payroll installments, and up to 12 months of COBRA premiums paid by the company if he timely elects coverage. All of his outstanding equity awards immediately vest as of the effective date, and his stock option exercise period is extended until the earlier of December 31, 2027 or each option’s normal expiration, subject to earlier termination on a change in control. His performance stock units may still vest based on revenue and gross margin goals through December 31, 2026, or at target if a change in control occurs by that date. In return, he provides a general release and waiver of claims.

Filing Explained

This amendment describes the separation agreement that became effective on August 7, 2026, but says the complete agreement will be filed later as an exhibit to the company’s Form 10-Q for the quarter ending September 30, 2026.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Severance duration: 12 months of base salary COBRA coverage end date: August 31, 2026 COBRA premiums period: twelve (12) months +4 more

7 metrics

Severance duration 12 months of base salary Cash severance equal to 12 months of base salary paid after the Separation Date

COBRA coverage end date August 31, 2026 Eligibility to elect continued health, dental and vision benefits under COBRA through this date

COBRA premiums period twelve (12) months Company will pay COBRA premiums for up to twelve months if coverage is timely elected

Option exercise extension December 31, 2027 Latest date to exercise outstanding options, or earlier normal expiration, subject to change in control

PSU performance period end December 31, 2026 Deadline to achieve revenue and gross margin goals for performance stock unit vesting

CEO Separation Date August 3, 2026 Date Antony Koblish ceased serving as Chief Executive Officer

Agreement Effective Date August 7, 2026 Effective date of the Separation Agreement and General Release

Key Terms

Separation Agreement and General Release, Consolidated Omnibus Budget Reconciliation Act, COBRA, change in control, +1 more

5 terms

Separation Agreement and General Release regulatory

"the Company and Mr. Koblish entered into a Separation Agreement and General Release"

Consolidated Omnibus Budget Reconciliation Act regulatory

"coverage under the Company’s health, dental and vision benefits pursuant to the Consolidated Omnibus Budget Reconciliation Act"

COBRA regulatory

"eligible to elect to continue coverage under the Company’s health, dental and vision benefits pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”)"

COBRA is a U.S. federal law that lets employees and their dependents temporarily keep employer-sponsored health insurance after job loss, reduction in hours, or other qualifying events by paying the premiums themselves. Investors should care because offering COBRA can affect a company’s cash flow, administrative costs and legal disclosures when workforce changes occur—similar to a former club member paying to keep their membership active after leaving the club.

change in control financial

"subject to earlier termination in the event of a change in control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

performance stock units financial

"Mr. Koblish’s performance stock units shall remain outstanding and eligible to vest"

Performance stock units are a type of company award that grants employees shares of stock only if certain performance goals are met. They motivate employees to work toward specific company achievements, aligning their interests with those of shareholders. For investors, they can influence a company's future stock supply and reflect management’s confidence in reaching key targets.

FAQ

What does TELA (TELA) disclose in this amended 8-K about its former CEO?

TELA Bio details a Separation Agreement and General Release with former CEO Antony Koblish, effective August 7, 2026. It describes cash severance, continued benefits, accelerated equity vesting, extended option exercise periods and treatment of performance stock units.

What severance pay will former TELA (TELA) CEO Antony Koblish receive?

Antony Koblish will receive 12 months of his base salary, paid in substantially equal installments under TELA Bio’s normal payroll schedule. He also receives all accrued and unpaid base salary through the August 3, 2026 separation date.

How are health benefits handled in TELA (TELA) CEO separation agreement?

Koblish remains eligible for continued health, dental and vision coverage under COBRA through August 31, 2026. If he timely elects COBRA by September 1, 2026, TELA Bio will pay his COBRA premiums for up to 12 months on active-employee terms.

What happens to Antony Koblish’s equity awards under the TELA (TELA) agreement?

All of Koblish’s equity awards immediately accelerate and become fully vested as of the August 7, 2026 effective date. His options’ exercise period is extended until the earlier of December 31, 2027 or the options’ normal expiration, subject to earlier termination on a change in control.

How are performance stock units treated in the TELA (TELA) CEO separation?

Koblish’s performance stock units remain outstanding and can vest based on revenue and gross margin goals achieved by December 31, 2026. If a change in control transaction occurs by that date, those performance stock units vest at target.

Does the TELA (TELA) separation agreement include a release of claims?

Yes. As part of the Separation Agreement and General Release, Koblish agrees to a general release and waiver of claims against TELA Bio. This release is a condition tied to the compensation and benefits described in the agreement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Available on EDGAR 08/13/2026 - 04:06 PM Accepted by SEC EDGAR 08/13/2026 - 04:05 PM Learn about SEC filing dates

false 0001561921 0001561921 2026-08-03 2026-08-03 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 3, 2026

TELA Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39130		45-5320061
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1 Great Valley Parkway, Suite 24 Malvern, Pennsylvania		19355
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (484) 320-2930

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		TELA		Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Explanatory Note

This Amendment No. 1 to the Current Report on Form 8-K supplements and amends Item 5.02 of the Current Report on Form 8-K filed on August 4, 2026 (the “Original Form 8-K”) to disclose information regarding material modifications to a material compensatory plan, contract or arrangement as to which a named executive officer of the registrant participates that were effected pursuant to an agreement entered into subsequent to the filing of the Original Form 8-K. No other changes have been made to the Original Form 8-K.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As reported in the Original Form 8-K, the Board of Directors (the “Board”) of TELA Bio, Inc. (the “Company”) determined that Antony Koblish will no longer serve as the Company’s Chief Executive Officer as of August 3, 2026 (the “Separation Date”) and that the Company and Mr. Koblish expected to enter into a separation agreement.

On August 7, 2026 (the “Effective Date”), the Company and Mr. Koblish entered into a Separation Agreement and General Release (the “Separation Agreement”). Pursuant to the Separation Agreement, Mr. Koblish will receive all accrued and unpaid base salary through the Separation Date and will remain eligible to elect to continue coverage under the Company’s health, dental and vision benefits pursuant to the Consolidated Omnibus Budget Reconciliation Act (“COBRA”) through August 31, 2026. Further, pursuant to the Separation Agreement, Mr. Koblish will receive an amount equal to 12 months of his base salary rate in effect immediately prior to the Separation Date, paid ratably in substantially equal installments in accordance with the Company’s payroll practice over 12 months, beginning on the first payroll date following the Effective Date. If Mr. Koblish timely elects to continue his health, dental and vision coverage under COBRA by September 1, 2026, the Company will pay COBRA premiums on Mr. Koblish’s behalf for a period of twelve (12) months, under the same terms and conditions as if Mr. Koblish was an active employee. Mr. Koblish’s equity awards granted under the Company’s Amended and Restated 2019 Equity Incentive Plan, as amended, and any other equity plan shall all immediately accelerate and become fully vested and exercisable or nonforfeitable as of the Effective Date. Mr. Koblish’s option excise period for any outstanding options (including any options accelerated in accordance with the above) shall be extended until the earlier of (i) December 31, 2027 and (ii) the applicable expiration date of such options, subject to earlier termination in the event of a change in control. Mr. Koblish’s performance stock units shall remain outstanding and eligible to vest upon the achievement of certain annual revenue and gross margin goals to the extent achieved on or prior to December 31, 2026; provided that if a change in control transaction occurs on or prior to December 31, 2026, such performance stock units shall vest at target. Additionally, Mr. Koblish agreed to a general release and waiver of claims against the Company.

The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Separation Agreement, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TELA BIO, INC.
By:	/s/ Roberto Cuca
Name:	Roberto Cuca
Title:	Chief Operating Officer; Chief Financial Officer and Corporate Secretary

Date: August 13, 2026

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 2.9 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 33.4 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 21.8 KB